Seroprevalence of hepatitis C and associated risk factors in urban areas of Antananarivo, Madagascar.
BACKGROUND
The risk factors for the transmission of HCV vary substantially between countries and geographic regions. The overall prevalence in south and east Africa region has been estimated to be 1.6% but limited information about the epidemiology of HCV infection in Madagascar is available


METHODS
A cross-sectional survey for hepatitis C antibodies was conducted in 2,169 subjects of the general population of Antananarivo to determine seroprevalence of hepatitis C and associated risk factors.


RESULTS
The overall seroprevalence was 1.2% (25/2,169). The prevalence did not differ significantly according to gender but it increased with age (Chi2 tendency test, p < 10-5). The variable history of hospitalization, previous therapeutic injections, dental treatment, intravenous drug use, and abnormal ALT and AST were statistically significantly related with the presence of HCV antibodies. No relationship with past history of blood transfusion was observed.


CONCLUSIONS
HCV prevalence in Madagascar seems to be similar to that in most other east African countries. Age appears to be an important risk factor. Iatrogenic causes of HCV transmission need to be further evaluated because all HCV cases had a history of receiving therapeutic injections and data suggested a cumulative effect in relation with therapeutic injections.
Ramarokoto
Charles E
CE
Unité d'Epidémiologie, Institut Pasteur de Madagascar, BP 1274, Antananarivo 101, Madagascar. charlesr@pasteur.mg
Rakotomanana
Fanjasoa
F
Ratsitorahina
Maherisoa
M
Raharimanga
Vaomalala
V
Razafindratsimandresy
Richter
R
Randremanana
Rindra
R
Rakoto-Andrianarivelo
Mala
M
Rousset
Dominique
D
Andrianaja
Voahangy
V
Richard
Vincent
V
Soares
Jean-Louis
JL
Rabarijaona
Leon P
LP
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D002648:Child; D002675:Child, Preschool; D003430:Cross-Sectional Studies; D005260:Female; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics / Q000276:immunology; D006526:Hepatitis C / Q000097:blood / Q000453:epidemiology* / Q000635:transmission; D018937:Hepatitis C Antibodies / Q000097:blood*; D006801:Humans; D016015:Logistic Models; D008270:Madagascar / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D016036:Seroepidemiologic Studies; D014504:Urban Health / Q000706:statistics & numerical data*
D018937:Hepatitis C Antibodies